Effect of eriodictyol on the development of atopic dermatitis-like lesions in ICR mice

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 8, 2013, Pages 1375-1379

  Park, Sae Jin ^a   Lee, Yong Hyeon ^a   Lee, Kwang Ho ^b   Kim, Tack Joong ^a  

^a Yonsei University Wonju   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

Atopic dermatitis; Eriodictyol; Scratching behavior; Skin severity

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ERIODICTYOL; IMMUNOGLOBULIN E;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EPIDERMIS; HISTOLOGY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; SCRATCHING; SKIN DEFECT; SKINFOLD;

EID: 84883173866     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00296     Document Type: Article

References (24)

1. Cooper KD. Atopic dermatitis: recent trends in pathogenesis and therapy. J. Invest. Dermatol., 102, 128-137 (1994).
2. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet, 351, 1715-1721 (1998).
3. Gao XK, Nakamura N, Fuseda K, Tanaka H, Inagaki N, Nagai H. Establishment of allergic dermatitis in NC/Nga mice as a model for severe atopic dermatitis. Biol. Pharm. Bull., 27, 1376-1381 (2004).
4. Ikezawa Z, Komori J, Ikezawa Y, Inoue Y, Kirino M, Katsuyama M, Aihara M. A Role of Staphyococcus aureus, interleukin-18, nerve growth factor and semaphorin 3A, an axon guidance molecule, in pathogenesis and treatment of atopic dermatitis. Allergy Asthma Immunol. Res., 2, 235-246 (2010).
5. Niebuhr M, Werfel T. Innate immunity, allergy and atopic dermatitis. Curr. Opin. Allergy Clin. Immunol., 10, 463-468 (2010).
6. Jiang J, Yamaguchi T, Funakushi N, Kuhara T, Fan PS, Ueki R, Suto H, Kase Y, Ikeda S, Ogawa H. Oral administration of Yokukansan inhibits the development of atopic dermatitis-like lesions in isolated NC/Nga mice. J. Dermatol. Sci., 56, 37-42 (2009).
7. Wierenga EA, Snoek M, Jansen HM, Bos JD, van Lier RA, Kapsenberg ML. Human atopen-specific types 1 and 2 T helper cell clones. J. Immunol., 147, 2942-2949 (1991).
8. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, Krieg T, Stanzel S, Heinrich PC, Merk HF, Bosio A, Baron JM, Hermanns HM. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J. Allergy Clin. Immunol., 118, 930-937 (2006).
9. Ingber A. What's new in contact dermatitis: allergy to topical steroids in Israeli patients with contact dermatitis. Isr. Med. Assoc. J., 4 (II Suppl.), 867 (2002).
10. Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y, Koga T. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br. J. Dermatol., 148, 128-133 (2003).
11. Kobayashi H, Ishii M, Takeuchi S, Tanaka Y, Shintani T, Yamatodani A, Kusunoki T, Furue M. Efficacy and safety of a traditional herbal medicine, Hochu-ekki-to in the long-term management of kikyo (delicate constitution) patients with atopic dermatitis: A 6-month, multicenter, double-blind, randomized, placebo-controlled study. Evid. Based Complement. Alternat. Med., 7, 367-373 (2010).
12. Vandeputte OM, Kiendrebeogo M, Rasamiravaka T, Stévigny C, Duez P, Rajaonson S, Diallo B, Mol A, Baucher M, El Jaziri M. The flavanone naringenin reduces the production of quorum sensingcontrolled virulence factors in Pseudomonas aeruginosa PAO1. Microbiology, 157, 2120-2132 (2011).
13. Lee JK. Anti-inflammatory effects of eriodictyol in lipopolysaccharide- stimulated raw 264.7 murine macrophages. Arch. Pharm. Res., 34, 671-679 (2011).
14. Yoo JM, Kim JH, Park SJ, Kang YJ, Kim TJ. Inhibitory effect of eriodictyol on IgE/Ag-induced type I hypersensitivity. Biosci. Biotechnol. Biochem., 76, 1285-1290 (2012).
15. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, Matsumoto M, Ushio H, Saito S, Askenase PW, Ra C. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int. Immunol., 9, 461-466 (1997).
16. Maekawa T, Yamaguchi-Miyamoto T, Nojima H, Kuraishi Y. Effects of naltrexone on spontaneous itch-associated responses in NC mice with chronic dermatitis. Jpn. J. Pharmacol., 90, 193-196 (2002).
17. Metzger H. The receptor with high affinity for IgE. Immunol. Rev., 125, 37-48 (1992).
18. Kawakami T, Ando T, Kimura M, Wilson BS, Kawakami Y. Mast cells in atopic dermatitis. Curr. Opin. Immunol., 21, 666-678 (2009).
19. Geha RS. Allergy and hypersensitivity. Nature versus nurture in allergy and hypersensitivity. Curr. Opin. Immunol., 15, 603-608 (2003).
20. Leung DY, Bieber T. Atopic dermatitis. Lancet, 361, 151-160 (2003).
21. Pokharel YR, Lim SC, Kim SC, Heo TH, Choi HK, Kang KW. Sopungyangjae-tang inhibits development of dermatitis in NC/NGA mice. Evid. Based Complement. Alternat. Med., 5, 173-180 (2008).
22. Yang G, Lee K, Lee MH, Kim SH, Ham IH, Choi HY. Inhibitory effects of Chelidonium majus extract on atopic dermatitis-like skin lesions in NC/Nga mice. J. Ethnopharmacol., 138, 398-403 (2011).
23. Fujii Y, Takeuchi H, Sakuma S, Sengoku T, Takakura S. Characterization of a 2,4-dinitrochlorobenzene-induced chronic dermatitis model in rats. Skin Pharmacol. Physiol., 22, 240-247 (2009).
24. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, Torii H, Asahina A, Onai N, Matsushima K, Tamaki K. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J. Allergy Clin. Immunol., 107, 535-541 (2001).